School of Medicine Publications and Presentations
Document Type
Article
Publication Date
3-7-2022
Abstract
Multidrug resistance (MDR) is one of the major therapeutic challenges that limits the efficacy of chemotherapeutic response resulting in poor prognosis of ovarian cancer (OC). The multidrug resistance protein 1 (MRP1) is a membrane-bound ABC transporter involved in cross resistance to many structurally and functionally diverse classes of anticancer drugs including doxorubicin, taxane, and platinum. In this study, we utilize homology modelling and molecular docking analysis to determine the binding affinity and the potential interaction sites of MRP1 with Carboplatin, Gemcitabine, Doxorubicin, Paclitaxel, and Topotecan. We used AutoDock Vina scores to compare the binding affinities of the anticancer drugs against MRP1. Our results depicted Carboplatin < Gemcitabine < Topotecan < Doxorubicin < Paclitaxel as the order of binding affinities. Paclitaxel has shown the highest binding affinity whereas Carboplatin displayed the lowest affinity to MRP1. Interestingly, our data showed that Carboplatin, Paclitaxel, and Topotecan bind specifically to Asn510 residue in the transmembrane domains 1 of the MRP1. Our results suggest that Carboplatin could be an appropriate therapeutic choice against MRP1 in OC as it couples weakly with Carboplatin. Further, our findings also recommend opting Carboplatin with Gemcitabine as a combinatorial chemotherapeutic approach to overcome MDR phenotype associated with recurrent OC. View Full-Text
Recommended Citation
Haque, A.; Baig, G.A.; Alshawli, A.S.; Sait, K.H.W.; Hafeez, B.B.; Tripathi, M.K.; Alghamdi, B.S.; MohammedAli, H.S.H.; Rasool, M. Interaction Analysis of MRP1 with Anticancer Drugs Used in Ovarian Cancer: In Silico Approach. Life 2022, 12, 383. https://doi.org/10.3390/ life12030383
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Publication Title
Life
DOI
10.3390/life12030383
Academic Level
faculty
Mentor/PI Department
Immunology and Microbiology
Comments
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.